Yonsei Med J.  1989 Dec;30(4):355-366. 10.3349/ymj.1989.30.4.355.

Exogenous surfactant replacement therapy of hyaline membrane disease in premature infants

• Namgung R
• Lee C
• Suh JS
• Park KI
• Han DG

• KMID: 1105564
• DOI: http://doi.org/10.3349/ymj.1989.30.4.355

Abstract

We conducted a clinical trial to assess whether surfactant-TA given within the first six hours of life could improve oxygenation and reduce the ventilatory support in premature infants with hyaline membrane disease (HMD) during the first 24 hours of life. Eight premature infants with severe HMD requiring ventilation were treated, at a mean age of 2.72 hours, with a single intratracheal instillation of surfactant-TA (120 mg/kg). Arterial oxygenation improved dramatically as reflected by the increase of the a/A PO2 ratio and PaO2 to about 2 times the pretreatment values within 3 hours after surfactant treatment. And thus, oxygen concentrations (FiO2) could be reduced and remained significantly lower than pretreatment values during the first 24 hours after treatment. Infants given surfactant-TA required lower mean airway pressure (MAP) and had a significantly decreased ventilatory index (VI) during the first 24 hours after treatment, which reflect the decreased requirement for ventilatory support. Chest radiograph scores significantly improved within 24 hours after treatment compared with pretreatment scores. In this trial, we found that a single intratracheal dose of surfactant-TA given to infants with HMD resulted in improved respiratory status and radiographic findings during the first 24 hours after treatment.

Keyword

Surfactant replacement therapy; HMD in premature infants

MeSH Terms

Blood Gas Analysis/methods
Clinical Trials
Human
Hyaline Membrane Disease/*drug therapy/radiography
Infant, Newborn
Oxygen/administration and dosage
Pulmonary Surfactants/administration and dosage/*therapeutic use
Respiration